• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic wins CE Mark for next-gen InterStim products

Medtronic wins CE Mark for next-gen InterStim products

January 13, 2020 By Sean Whooley

Medtronic logo updatedMedtronic (NYSE:MDT) announced today that it received CE Mark approval for its InterStim Micro neurostimulator and InterStim SureScan MRI leads.

The medtech giant plans to make the products available on the market on Jan. 15 to expand access to sacral neuromodulation (SNM) therapy for European patients, according to a news release.

InterStim Micro is a rechargeable device designed to deliver SNM therapy for the treatment of overactive bladder, fecal incontinence and non-obstructive urinary retention. It is made to be 80% smaller than the already-existing InterStim II neurostimulator and is touted to have a life span of 15 years with its Overdrive battery technology.

The platform is slated to use the SureScan leads, which are designed to allow for full-body 1.5 and 3 Tesla MRI-conditional scans

“We’re excited our most recent technology advances in sacral neuromodulation will allow physicians to treat more patients who need relief from their symptoms,” said Brooke Story, VP & GM of Medtronic’s pelvic health & gastric therapies business.

“We pioneered this therapy 25 years ago in partnership with physicians, and we have the only five-year data for all indications to demonstrate its safety and efficacy,” Story said in a news release. “We know from deep experience that it’s important the therapy accommodates the lifestyle of the patient to produce the best outcome, and our latest innovations will now offer them a lifestyle-friendly choice in Medtronic SNM systems.”

Dr. Philip E.V. Van Kerrebroeck, a urology professor at Maastricht University Medical Center (Maastricht, The Netherlands), described long-term bladder and bowel control as an under-met medical need.

“The new capabilities offered by MRI-conditional InterStim II and InterStim Micro will give patients the ability to choose a system that is compatible with their lifestyle, and they can have an MRI without being explanted,” Van Kerrebroeck said. “I’m excited because it allows me to offer the trusted experience and support of Medtronic to help give my patients their lives back.”

Filed Under: Featured, Neuromodulation/Neurostimulation, Regulatory/Compliance Tagged With: CE Mark, Medtronic

More recent news

  • Penumbra completes enrollment in pulmonary embolism trial
  • Zoll opens new facility in Rhode Island
  • FDA expands clearance for Inquis Medical’s Aventus thrombectomy system
  • SS Innovations completes first robotic cardiac surgery in the Americas
  • GI Windows wins FDA nod for magnet tech

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy